Suresh V. Dange
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Suresh V. Dange has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
K U Shah
3 shared publicationsD S Shrotri
2 shared publicationsA P Saraf
1 shared publicationA S Deshpande
1 shared publicationA. A. Joshi
Department of Pharmacology, B. J. Medical College, Pune 1, India
1 shared publicationAbhijeet Tilak
1 shared publication
Latest Publications
- Open Access
- 31 January 2016
- Published by Siddharth Health Research and Social Welfare Society in International Journal of Medical Research & Review
- Vol. 4 (1) , 55-59
Assessment of effectiveness of nonspecific antidiarrheal agents in reducing the need for intravenous rehydration in children with acute diarrhea
Background: In clinical practice, nonspecific antidiarrheals are most commonly used by clinicians along with routine treatment to hasten the recovery and to give psychological reassurance. This study was conducted to assess the effectiveness of nonspecific antidiarrheal agents in reducing the need for intravenous rehydration in children with acute diarrhea. Materials and Methods: This was a prospective, observational study done in clinical settings for a period of 3 years at two pediatric clinics and at a tertiary care hospital. Children were divided into 5 treatment groups (viz, control, racecadotril, Mebarid, Diarex and loperamide) at the discretion of the pediatrician. One questionnaire was provided to parents to record the details about the course of diarrhea. Parents were sensitized to report any episode of complication or need for intravenous fluids. Results: The unscheduled need for intravenous fluids due to dehydration was significantly higher in control group compared to other groups {Control: 7.37%, Racecadotril : 1.71% Mebarid: 2.4%, Diarex: 0%, Loperamide : 0%)}. Conclusion: Present study suggests that use of nonspecific antidiarrheals may decrease the need for admission for intravenous fluids in children with acute diarrhea.
- 31 January 2016
- Published by Siddharth Health Research and Social Welfare Society in International Journal of Medical Research & Review
- Vol. 4 (1) , 55-59
Open AccessAssessment of effectiveness of nonspecific antidiarrheal agents in reducing the need for intravenous rehydration in children with acute diarrhea
Background: In clinical practice, nonspecific antidiarrheals are most commonly used by clinicians along with routine treatment to hasten the recovery and to give psychological reassurance. This study was conducted to assess the effectiveness of nonspecific antidiarrheal agents in reducing the need for intravenous rehydration in children with acute diarrhea. Materials and Methods: This was a prospective, observational study done in clinical settings for a period of 3 years at two pediatric clinics and at a tertiary care hospital. Children were divided into 5 treatment groups (viz, control, racecadotril, Mebarid, Diarex and loperamide) at the discretion of the pediatrician. One questionnaire was provided to parents to record the details about the course of diarrhea. Parents were sensitized to report any episode of complication or need for intravenous fluids. Results: The unscheduled need for intravenous fluids due to dehydration was significantly higher in control group compared to other groups {Control: 7.37%, Racecadotril : 1.71% Mebarid: 2.4%, Diarex: 0%, Loperamide : 0%)}. Conclusion: Present study suggests that use of nonspecific antidiarrheals may decrease the need for admission for intravenous fluids in children with acute diarrhea.
- 1 July 1992
- Vol. 36 (3) , 205-8
Comparison of bioavailability and pharmacodynamics of diltiazem from two pharmaceutical preparations.
Diltiazem, a calcium channel blocker, is used in multiple divided doses daily, due to its short elimination half-life. Hence, administration as a modified release (MR) formulation is suggested. In this double blind cross-over trial, the pharmacokinetics and pharmacodynamics of diltiazem was studied in eight healthy Indian adults. Diltiazem was administered as single dose (60 mg) of the two formulations viz immediate release (IR) and MR. Venous blood samples, for estimation of diltiazem by HPLC, were collected at frequent intervals and BP, HR and ECG were monitored during the 12h study period. With MR formulation, plasma half-life was significantly (P < 0.05) prolonged (6.25 +/- 1.2 h vs. 2.69 +/- 0.2 h), the extent of alterations in BP, HR and PR interval was significantly less, while the duration of prolongation of PR interval was significantly more as compared to IR formulation. Therefore, MR formulation of diltiazem has better pharmacokinetic and pharmacodynamic profile as compared to IR formulation.
- 1 July 1992
- Vol. 36 (3) , 205-8
Comparison of bioavailability and pharmacodynamics of diltiazem from two pharmaceutical preparations.
Diltiazem, a calcium channel blocker, is used in multiple divided doses daily, due to its short elimination half-life. Hence, administration as a modified release (MR) formulation is suggested. In this double blind cross-over trial, the pharmacokinetics and pharmacodynamics of diltiazem was studied in eight healthy Indian adults. Diltiazem was administered as single dose (60 mg) of the two formulations viz immediate release (IR) and MR. Venous blood samples, for estimation of diltiazem by HPLC, were collected at frequent intervals and BP, HR and ECG were monitored during the 12h study period. With MR formulation, plasma half-life was significantly (P < 0.05) prolonged (6.25 +/- 1.2 h vs. 2.69 +/- 0.2 h), the extent of alterations in BP, HR and PR interval was significantly less, while the duration of prolongation of PR interval was significantly more as compared to IR formulation. Therefore, MR formulation of diltiazem has better pharmacokinetic and pharmacodynamic profile as compared to IR formulation.
- Open Access
- 1 October 1990
- Vol. 10 (2) , 94-7
Clinical evaluation of terminalia belerica in diarrhoea.
Terminalia belerica (behada) fruit has been evaluated as a promising agent against E. histolytica and a variety of bacteria associated with dysentery and diarrhoea. These in vitro studies were extended further for evaluating clinical efficacy among patients of acute and chronic cases of diarrhoea and dysentery. The Studies were carried out on 25 patients by five medical practitioners practicing at different clinics in the urban areas of Pune. The data was collected as per the protocol given to the concerned clinicians. Inclusion and exclusion criteria were critically followed. Record of patients' history, clinical evaluations and investigations like stool, urine examination were carried out where necessary.The maximum treatment period was 14 days and the dose was 150 mg. tablets of bioactive fraction three times a day. 11 out of 12 patients responded to therapy and required around twelve tablets for recovery. Seven patients having the presence of cyst of amoeba, E. coli etc. became negative at the end of treatment. Improvement started on second day. No side effects of any nature were observed.
- 1 October 1990
- Vol. 10 (2) , 94-7
Open AccessClinical evaluation of terminalia belerica in diarrhoea.
Terminalia belerica (behada) fruit has been evaluated as a promising agent against E. histolytica and a variety of bacteria associated with dysentery and diarrhoea. These in vitro studies were extended further for evaluating clinical efficacy among patients of acute and chronic cases of diarrhoea and dysentery. The Studies were carried out on 25 patients by five medical practitioners practicing at different clinics in the urban areas of Pune. The data was collected as per the protocol given to the concerned clinicians. Inclusion and exclusion criteria were critically followed. Record of patients' history, clinical evaluations and investigations like stool, urine examination were carried out where necessary.The maximum treatment period was 14 days and the dose was 150 mg. tablets of bioactive fraction three times a day. 11 out of 12 patients responded to therapy and required around twelve tablets for recovery. Seven patients having the presence of cyst of amoeba, E. coli etc. became negative at the end of treatment. Improvement started on second day. No side effects of any nature were observed.
- 1 October 1986
- Vol. 30 (4) , 347-50
Effect of some drugs on blood pressure and heart rate of anaesthetized dogs during experimentally induced acidosis and alkalosis.
- 1 October 1986
- Vol. 30 (4) , 347-50
Effect of some drugs on blood pressure and heart rate of anaesthetized dogs during experimentally induced acidosis and alkalosis.
- 1 April 1985
- Vol. 29 (2) , 129-31
Potentiation of antipyretic effect of acetaminophen by concomitant administration of ascorbic acid.
- 1 April 1985
- Vol. 29 (2) , 129-31
Potentiation of antipyretic effect of acetaminophen by concomitant administration of ascorbic acid.
- 6 May 1984
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 24 (5-6) , 267-270
Effects of Enfenamic Acid on Renal Electrolyte Excretion in Hypertensive Patients
Single and multiple doses of enfenamic acid were compared in hypertensive patients with those of hydrochlorothiazide using urinary output and electrolytes as parameters. With enfenamic acid, excretion of Na+, K+, and Cl- was significantly decreased in the multiple-dose study; after single doses, there was a significant decrease in the excretion of Na+ and Cl- only.
- 6 May 1984
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 24 (5-6) , 267-270
Effects of Enfenamic Acid on Renal Electrolyte Excretion in Hypertensive Patients
Single and multiple doses of enfenamic acid were compared in hypertensive patients with those of hydrochlorothiazide using urinary output and electrolytes as parameters. With enfenamic acid, excretion of Na+, K+, and Cl- was significantly decreased in the multiple-dose study; after single doses, there was a significant decrease in the excretion of Na+ and Cl- only.